Target
hepatocellular carcinoma
4 abstracts
Abstract
Efficacy and safety of donafenib as adjuvant therapy for patients with hepatocellular carcinoma undergoing curative resection: A retrospective, multicenter cohort study.Org: Li Huili Hospital,
Abstract
Incorporation of fellow-driven, interactive case-based discussions to improve fellowship education in a new fellowship program.Org: The University of Texas Health Science Center at Houston (UTHealth Houston) McGovern Medical School, University of Texas at Houston, University of Texas Health Sciences Center at Houston, University of Texas at Houston Health Science Center,
Abstract
Using machine learning-based boosting algorithm to predict hepatotoxicity after local therapy and association with survival in patients undergoing liver directed therapy.Org: Montefiore Medical Center, Albert Einstein College of Medicine, Albert B. Sabin Vaccine Institute, Albert Einstein College of Medicine - Montefiore Medical Center,
Abstract
Donafenib, anti-PD-1 antibodies, plus hepatic arterial infusion chemotherapy (HAIC) as conversion therapy in patients with initially unresectable hepatocellular carcinoma (HCC): A prospective, single-arm, phase 2 study.Org: The Fifth Medical Center of the PLA General Hospital, The Fifth Medical Center of Chinese PLA General Hospital,